Page 123 - Read Online

Zanetto et al. Hepatoma Res 2018;4:70 I http://dx.doi.org/10.20517/2394-5079.2018.102 Page 13 of 16

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, et al. Specific issues concerning the management of patients on the
waiting list and after liver transplantation. Liver Int 2018;38:1338-62.
2. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis
C and decompensated cirrhosis. J Hepatol 2016;64:1224-31.
3. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4
hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685-
97.
4. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92.
5. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with
advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493-505.
6. Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, et al. Effect of viral suppression on hepatic venous pressure gradient in
hepatitis C with cirrhosis and portal hypertension. J Viral Hepat 2017;24:823-31.
7. Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, et al. Effects of all-oral anti-viral therapy on HVPG and systemic
hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017;153:1273-83.
8. Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, et al. Sustained virologic response to interferon-free therapies ameliorates
HCV-induced portal hypertension. J Hepatol 2016;65:692-9.
9. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, et al. Delisting of liver transplant candidates with chronic hepatitis
C after viral eradication: a European study. J Hepatol 2016;65:524-31.
10. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting
liver transplantation. J Hepatol 2017;67:1168-76.
11. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, et al. Effects of eradicating hepatitis C virus infection in patients with
cirrhosis differ with stage of portal hypertension. Gastroenterology 2016;151:130-9.
12. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular
carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
13. Janjua NZ, Chong M, Kuo M, Woods R, Wong J, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in
patients with hepatitis C in Canada. J Hepatol 2017;66:504-13.
14. Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting
antivirals. Hepatology 2016;64:1442-50.
15. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
Hepatology 2017;65:804-12.
16. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, et al. Assessment of cost of innovation versus the value of health gains associated
with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care. Medicine (Baltimore) 2016;95:e5048.
17. Tapper EB, Afdhal NH, Curry MP. Before or after transplantation? A review of the cost effectiveness of treating waitlisted patients with
hepatitis C. Transplantation 2017;101:933-7.
18. European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol 2016;64:433-85.
19. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-94.
20. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults
infected with hepatitis C virus. Hepatology 2015;62:932-54.
21. Cucchetti A, D’Amico G, Trevisani F, Morelli MC, Vitale A, et al. Effect of direct-acting antivirals on future occurrence of hepatocellular
carcinoma in compensated cirrhotic patients. Dig Liver Dis 2018;50:156-62.
22. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
N Engl J Med 2014;370:1483-93.
23. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in